Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology, Orthopedic |
Therapuetic Areas: | Neurology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 12/12/2018 |
Start Date: | December 2014 |
End Date: | August 31, 2019 |
Contact: | David Simpson, MD |
Email: | david.simpson@mssm.edu |
Phone: | 212-241-8748 |
Comparison of Electrophysiologic And Ultrasound Guidance For Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia And Spasticity
This study seeks to compare the use of ultrasound and electrophysiologic techniques to target
muscles for the treatment of spasticity and focal dystonia of the limbs. The purpose of this
study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT)
injection for the treatment of focal hand dystonia and upper limb spasticity.
Electrophysiologic guidance, using electrical stimulation, and ultrasound are the standard
ways of locating muscles during a treatment of BoNT injection.
muscles for the treatment of spasticity and focal dystonia of the limbs. The purpose of this
study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT)
injection for the treatment of focal hand dystonia and upper limb spasticity.
Electrophysiologic guidance, using electrical stimulation, and ultrasound are the standard
ways of locating muscles during a treatment of BoNT injection.
This is a study to investigate the use of two targeting techniques for botulinum toxin (BoNT)
injection for the treatment of focal hand dystonia and upper limb spasticity:
Electrophysiologic guidance, using electrical stimulation, and ultrasound. Subjects will be
selected from the clinical programs of both Icahn School of Medicine at Mount Sinai and the
National Institutes of Health who are already receiving onabotulinum toxin A injections
clinically. The study will consist of four visits. Visit one consists of screening subjects
who will then be consented and randomized to one of the two treatment techniques for their
ona-BoNT injection: 1) Electrophysiologic guidance using electrical stimulation or 2)
ultrasound. Visit 2 will occur at week 4 where the subjects will return for a follow up visit
to have blinded evaluator measurements of efficacy and strength and capture safety data.
Visit 3 will be at week 12 when subjects will cross over and have the alternate treatment
technique during their ona-BoNT injection. Visit 4 will occur at week 16 as the final
assessment where subjects will have measurements of efficacy and strength and capture safety
data by the blinded evaluator.
injection for the treatment of focal hand dystonia and upper limb spasticity:
Electrophysiologic guidance, using electrical stimulation, and ultrasound. Subjects will be
selected from the clinical programs of both Icahn School of Medicine at Mount Sinai and the
National Institutes of Health who are already receiving onabotulinum toxin A injections
clinically. The study will consist of four visits. Visit one consists of screening subjects
who will then be consented and randomized to one of the two treatment techniques for their
ona-BoNT injection: 1) Electrophysiologic guidance using electrical stimulation or 2)
ultrasound. Visit 2 will occur at week 4 where the subjects will return for a follow up visit
to have blinded evaluator measurements of efficacy and strength and capture safety data.
Visit 3 will be at week 12 when subjects will cross over and have the alternate treatment
technique during their ona-BoNT injection. Visit 4 will occur at week 16 as the final
assessment where subjects will have measurements of efficacy and strength and capture safety
data by the blinded evaluator.
Inclusion Criteria:
- 18 years or older
- Confirmed diagnosis of focal upper extremity dystonia (FHD) or upper limb spasticity
- Stable onabotulinumtoxinA dose regimen with a stable response as judged by the
physician and patient for at least 2 treatment sessions.
Exclusion Criteria:
- Contraindications to botulinum toxin
- Pregnancy or nursing
- Cognitive impairment that prevents reliable outcome measures of self-report
We found this trial at
2
sites
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
New York, New York 10029
(212) 241-6500
Principal Investigator: David Simpson, MD
Phone: 212-241-0784
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
Click here to add this to my saved trials